Alemtuzumab (Lemtrada)

Alemtuzumab otherwise known as Lemtrada is a disease modifying drug (DMD) for active relapsing remitting MS and very active relapsing remitting MS. it is given to you through an intravenous infusion (drip) each infusion will take approximately 4 hours. You will be closely monitored for 2 hours after each infusion. You will be given 8 infusions over the course of your treatment in year one you will receive 5 infusion over 5 consecutive days and year later you will receive a further 3 infusions over 3 consecutive days however you and your consultant may decided if you need any additional rounds of treatment this would only happen at least a year after your last round of treatment and would require you to undertake another 3 infusions over 3 consecutive days of treatment for each additional round your consultant decided you needed. you will need to be monitored monthly to detect potential side effects this will start after your first does these include blood test, urine test, self checks and yearly skin checks. these checks will last for at least 4 years after your last round of treatment

Side Effects

Common Side Effects Can Include

  • infusion-related reactions such as headache, rashes, fever and nausea.
  • infections including coughs, colds, chest infections and herpes virus infections (such as cold sores or shingles) infusion-related reactions such as headache, rashes, fever and nausea.
  • overactive or underactive thyroid
  • decrease in white blood cells (lymphopenia)
  • changes in blood pressure, heart rate
  • musculoskeletal pain

Less Common Side Effects can include

  • idiopathic thrombocytopenic purpura (ITP) a blood clotting disorder
  • kidney problems
  • thyroid disorders
  • increased levels of liver enzymes

A full list of side effects can be found in the manufacturer’s Patient Information Leaflet

What Lemtrada Patients Have To Say

I will shortly be adding lemtrada patients stories and experiences. please stay tuned thank you